Audentes Therapeutics (BOLD) Receives a Hold from William Blair

In a report released today, Raju Prasad from William Blair maintained a Hold rating on Audentes Therapeutics (BOLDResearch Report). The company’s shares closed last Monday at $28.61.

According to, Prasad is a 5-star analyst with an average return of 21.4% and a 61.2% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Alexion Pharmaceuticals, and Rocket Pharmaceuticals.

Currently, the analyst consensus on Audentes Therapeutics is a Moderate Buy with an average price target of $53.29, which is an 80.6% upside from current levels. In a report released today, Robert W. Baird also upgraded the stock to Hold with a $60.00 price target.

See today’s analyst top recommended stocks >>

Based on Audentes Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $45.74 million. In comparison, last year the company had a GAAP net loss of $36.29 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.